Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma.

ABSTRACT:

Background

Lung large-cell neuroendocrine carcinoma (L-LCNEC) is a rare and highly aggressive neuroendocrine tumor. There is currently no standard therapeutic regimen, and systemic chemotherapy results in poor prognosis. Due to the rarity of L-LCNEC, the efficacy and safety of immune checkpoint inhibitors (ICIs) remain unclear.

Methods

This study included 34 L-LCNEC patients administered ICIs at Zhejiang Cancer Hospital, from February 6, 2018 to February 6, 2023. The treatment responses were evaluated. Fisher's exact test was used to compare categorical variables, and the Kaplan-Meier method was used for survival analyses. Cox regression was used for multivariate analysis.

Results

The objective response rate (ORR) of 34 patients was 29.4%, the disease control rate (DC

SUBMITTER: Shi Z 

PROVIDER: S-EPMC10482626 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature